Lila Sciences

Lila Sciences is an ambitious AI-native biotech platform company founded in 2021, aiming to automate the entire scientific method. Its core offering, the 'AI Science Factory,' combines a proprietary AI model with autonomous laboratory hardware to accelerate R&D cycles from decades to months. While the company is private and likely pre-revenue, it has secured significant funding ($350M as of late 2025) and targets high-value discovery challenges across therapeutics, energy, materials, and more. Lila's success hinges on proving its platform's superiority over traditional research and other AI-driven approaches in generating validated, commercially viable discoveries.

Integrated 'Scientific Superintelligence' platform combining a proprietary AI model for hypothesis generation and design with the 'AI Science Factory,' a suite of autonomous robotic lab instruments for physical experimentation, forming a closed-loop system that autonomously executes the scientific method.

Lila competes in the broad AI-for-science space, facing pure-play AI drug discovery companies (e.g., Recursion, Exscientia), tech giants with life science units (e.g., Google's Isomorphic Labs, NVIDIA BioNeMo), and a growing number of integrated 'lab-in-the-loop' startups. Its key differentiator is the full-stack integration of AI with proprietary, automated physical lab infrastructure to create a closed discovery loop.